bo-0742 and 3-(9-acridinylamino)-5-hydroxymethylaniline

bo-0742 has been researched along with 3-(9-acridinylamino)-5-hydroxymethylaniline* in 1 studies

Other Studies

1 other study(ies) available for bo-0742 and 3-(9-acridinylamino)-5-hydroxymethylaniline

Article	Year
BO-0742, a derivative of AHMA and N-mustard, has selective toxicity to drug sensitive and drug resistant leukemia cells and solid tumors. Cancer letters, 2009, Apr-18, Volume: 276, Issue:2 This is a preclinical study of BO-0742, a derivative of 3-(9-acridinylamino)-5-hydroxymethyl-aniline (AHMA) and N-mustard, as an anti-cancer agent. MTS assays revealed a broad spectrum of anti-cancer activities in vitro, with the greatest cytotoxicity against leukemia and neuroblastoma including those with drug resistant characteristics, and a good therapeutic index with leukemia being 10-40 times more sensitive to BO-0742 than hematopoietic progenitors. Administration of BO-0742 at an optimal dose schedule based on its pharmacokinetics significantly suppressed the growth of xenografts of human breast and ovarian cancers in mice. Thus, BO-0742 is a potent anti-cancer agent worthy of further clinical development. Topics: Acridines; Aniline Compounds; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Drug Resistance, Neoplasm; Hematopoietic Stem Cells; Humans; Leukemia; Male; Mice; Multidrug Resistance-Associated Proteins; Neoplasms; Nitrogen Mustard Compounds; Xenograft Model Antitumor Assays	2009

Article

Year

BO-0742, a derivative of AHMA and N-mustard, has selective toxicity to drug sensitive and drug resistant leukemia cells and solid tumors.

Cancer letters, 2009, Apr-18, Volume: 276, Issue:2

This is a preclinical study of BO-0742, a derivative of 3-(9-acridinylamino)-5-hydroxymethyl-aniline (AHMA) and N-mustard, as an anti-cancer agent. MTS assays revealed a broad spectrum of anti-cancer activities in vitro, with the greatest cytotoxicity against leukemia and neuroblastoma including those with drug resistant characteristics, and a good therapeutic index with leukemia being 10-40 times more sensitive to BO-0742 than hematopoietic progenitors. Administration of BO-0742 at an optimal dose schedule based on its pharmacokinetics significantly suppressed the growth of xenografts of human breast and ovarian cancers in mice. Thus, BO-0742 is a potent anti-cancer agent worthy of further clinical development.

Topics: Acridines; Aniline Compounds; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Drug Resistance, Neoplasm; Hematopoietic Stem Cells; Humans; Leukemia; Male; Mice; Multidrug Resistance-Associated Proteins; Neoplasms; Nitrogen Mustard Compounds; Xenograft Model Antitumor Assays

2009